PHOSPHODIESTERASE 5 INHIBITORS EFFECTS ON ADAPTATION TO HIGH ALTITUDE, HAPE PREVENTION AND TREATMENT: A LITERATURE REVIEW
Abstract
Introduction: High-altitude pulmonary edema (HAPE) is a life-threatening, non-cardiogenic form of pulmonary edema that typically occurs within 2-4 days after rapid ascent above 2,500 meters. It is characterized by hypoxia-induced pulmonary hypertension, increased capillary hydrostatic pressure, and defected alveolar-capillary barrier integrity. Current preventive strategies include gradual ascent and acclimatization, while descent and supplemental oxygen remain the mainstays of treatment. Pharmacological options, including phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil and tadalafil, appear as promising agents due to their pulmonary vasodilatory effects mediated via the nitric oxide (NO)–cGMP pathway.
Description of the state of knowledge: This review synthesizes findings from clinical trials, case series, and mechanistic studies published in the last three decades to evaluate the efficacy and safety of PDE5 inhibitors in both the prevention and treatment of HAPE. Evidence indicates that sildenafil and tadalafil effectively reduce pulmonary artery pressure, improve oxygenation, and preserve endothelial barrier function under hypoxic conditions. Their prophylactic use significantly lowers HAPE incidence in high-risk individuals, while therapeutic administration has demonstrated clinical improvement in established cases, particularly when nifedipine use is contraindicated. However, results from some high-altitude trials remain inconclusive, and individual responses may vary based on ascent profile and susceptibility.
Conclusions: Overall, PDE5 inhibitors represent a viable adjunct in HAPE management. Further large-scale, randomized studies are necessary to clarify their optimal use, dosage, and comparative efficacy alongside existing pharmacologic options.
References
Wilkins, M. R., Ghofrani, H. A., Weissmann, N., Aldashev, A., & Zhao, L. (2015). Pathophysiology and treatment of high-altitude pulmonary vascular disease. Circulation, 131(6), 582–590. https://doi.org/10.1161/CIRCULATIONAHA.114.006977
Wu, T. Y., Ding, S. Q., Liu, J. L., Yu, M. T., Jia, J. H., Chai, Z. C., Dai, R. C., Zhang, S. L., Li, B. Y., Pan, L., Liang, B. Z., Zhao, J. Z., Qi, D. T., Sun, Y. F., & Kayser, B. (2007). Who should not go high: Chronic disease and work at altitude during construction of the Qinghai-Tibet railroad. High Altitude Medicine & Biology, 8(2), 88–107. https://doi.org/10.1089/ham.2007.1015
Singh, I., Kapila, C. C., Khanna, P. K., Nanda, R. B., & Rao, B. D. (1965). High-altitude pulmonary oedema. The Lancet, 1(7379), 229–234. https://doi.org/10.1016/S0140-6736(65)91520-5
Hackett, P. H., & Roach, R. C. (2001). High-altitude medicine. In P. S. Auerbach (Ed.), Wilderness medicine. St. Louis, MO: Mosby.
Bärtsch, P., & Swenson, E. R. (2003). High altitude pulmonary oedema. Swiss Medical Weekly, 133(27–28), 377–384.
Koul, P. A., Khan, U. H., Hussain, T., Koul, A. N., Malik, S., Shah, S., Bazaz, S. R., Rashid, W., & Jan, R. A. (2013). High altitude pulmonary edema among “Amarnath Yatris.” Lung India, 30(3), 193–198. https://doi.org/10.4103/0970-2113.116254
Bärtsch, P. (1999). High altitude pulmonary edema. Medicine & Science in Sports & Exercise, 31(1 Suppl), S23–S27.
Jones, B. E., Stokes, S., McKenzie, S., Nilles, E., & Stoddard, G. J. (2013). Management of high altitude pulmonary edema in the Himalaya: A review of 56 cases presenting at Pheriche medical aid post (4240 m). Wilderness & Environmental Medicine, 24(1), 32–36. https://doi.org/10.1016/j.wem.2012.07.004
Maggiorini, M., Mélot, C., Pierre, S., Pfeiffer, F., Greve, I., Sartori, C., et al. (2001). High-altitude pulmonary edema is initially caused by an increase in capillary pressure. Circulation, 103, 2078–2083.
Hopkins, S. R., Garg, J., Bolar, D. S., Balouch, J., & Levin, D. L. (2005). Pulmonary blood flow heterogeneity during hypoxia and high-altitude pulmonary edema. American Journal of Respiratory and Critical Care Medicine, 171, 83–87.
West, J. B., Tsukimoto, K., Mathieu-Costello, O., & Prediletto, R. (1991). Stress failure in pulmonary capillaries. Journal of Applied Physiology, 70, 1731–1742.
Swenson, E. R., Maggiorini, M., Mongovin, S., et al. (2002). Pathogenesis of high-altitude pulmonary edema: Inflammation is not an etiologic factor. JAMA, 287(17), 2228–2235. https://doi.org/10.1001/jama.287.17.2228
Duplain, H., Sartori, C., Lepori, M., Egli, M., Allemann, Y., Nicod, P., et al. (2000). Exhaled nitric oxide in high-altitude pulmonary edema: Role in the regulation of pulmonary vascular tone and evidence for a role against inflammation. American Journal of Respiratory and Critical Care Medicine, 162, 221–224.
Busch, T., Bärtsch, P., Pappert, D., Grünig, E., Hildebrandt, W., Elser, H., et al. (2001). Hypoxia decreases exhaled nitric oxide in mountaineers susceptible to high-altitude pulmonary edema. American Journal of Respiratory and Critical Care Medicine, 163, 368–373.
Ghofrani, H. A., Reichenberger, F., Kohstall, M. G., Mrosek, E. H., Seeger, T., Olschewski, H., et al. (2004). Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: A randomized, double-blind, placebo-controlled crossover trial. Annals of Internal Medicine, 141(3), 169–177. https://doi.org/10.7326/0003-4819-141-3-200408030-00005
Ricart, A., Maristany, J., Fort, N., Leal, C., Pagés, T., & Viscor, G. (2005). Effects of sildenafil on the human response to acute hypoxia and exercise. High Altitude Medicine & Biology, 6(1), 43–49. https://doi.org/10.1089/ham.2005.6.43
Reichenberger, F., Kohstall, M. G., Seeger, T., Olschewski, H., Grimminger, F., Seeger, W., et al. (2007). Effect of sildenafil on hypoxia-induced changes in pulmonary circulation and right ventricular function. Respiratory Physiology & Neurobiology, 159(2), 196–201. https://doi.org/10.1016/j.resp.2007.07.005
Iwase, M., Itou, Y., Takada, K., Shiino, K., Kato, Y., & Ozaki, Y. (2016). Altitude-induced pulmonary hypertension on one-day rapid ascent of Mount Fuji: Incidence and therapeutic effects of sildenafil. Echocardiography, 33(6), 838–843. https://doi.org/10.1111/echo.13189
Kolluru, G., Tamilarasan, K., Rajkumar, A., Geethapriya, S., Rajaram, M., Saleem, N., et al. (2008). Nitric oxide/cGMP protects endothelial cells from hypoxia-mediated leakiness. European Journal of Cell Biology, 87(3), 147–161. https://doi.org/10.1016/j.ejcb.2007.10.001
Cornolo, J., Mollard, P., Brugniaux, J. V., Robach, P., & Richalet, J.-P. (2004). Autonomic control of the cardiovascular system during acclimatization to high altitude: Effects of sildenafil. Journal of Applied Physiology, 97(3), 935–940. https://doi.org/10.1152/japplphysiol.00239
George, O. S., Singh, K., Kumar, B., Malhotra, V. K., & Jha, V. (2025). Proof of concept study: Alternative pharmacoprophylaxis for high-altitude pulmonary edema – A hospital-based randomized controlled trial. Medical Journal Armed Forces India, 81, 46–51.
Maggiorini, M., Brunner-La Rocca, H. P., Peth, S., Fischler, M., Böhm, T., Bernheim, A., et al. (2006). Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema. Annals of Internal Medicine, 145(7), 497. https://doi.org/10.7326/0003-4819-145-7-200610030-00007
Richalet, J. P., Gratadour, P., Robach, P., et al. (2005). Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine, 171, 275–281.
Bates, M. G. D., Thompson, A. A. R., Baillie, J. K., Sutherland, A. I., Irving, J. B., Hirani, N., et al. (2011). Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: Double blind, randomized, placebo-controlled trial. High Altitude Medicine & Biology, 12(3), 207–214. https://doi.org/10.1089/ham.2011.0007
Fagenholz, P. J., Gutman, J. A., Murray, A. F., & Harris, N. S. (2007). Treatment of high altitude pulmonary edema at 4240 m in Nepal. High Altitude Medicine & Biology, 8(2), 139–146. https://doi.org/10.1089/ham.2007.3055
Views:
0
Downloads:
0
Copyright (c) 2025 Wojciech Bednarz, Katarzyna Torbacka, Katarzyna Rozkosz, Joanna Kaczor, Zuzanna Wróbel, Olga Jakubik, Natalia Wróbel, Aleksandra Sosin, Patrycja Podlejska, Maja Torbacka
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
